Forte Biosciences (FBRX) EBITDA (2016 - 2026)
Forte Biosciences (FBRX) reported EBITDA of -$22.4 million for Q1 2026, down 43.22% year-over-year from -$39.5 million in Q1 2025, and down 170.71% quarter-over-quarter from $31.7 million in Q4 2025.
Forte Biosciences (FBRX) EBITDA (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of EBITDA data on file, last reported at -$22.4 million in Q1 2026.
- EBITDA for Q1 2026 came in at -$22.4 million, down 43.22% year-over-year; the trailing twelve-month figure through Mar 2026 was -$19.6 million (up 55.07% YoY), and the FY2025 annual result was -$14.4 million, up 59.54% from the prior year.
- EBITDA eased to -$22.4 million in Q1 2026 per FBRX's latest filing, from $31.7 million in the prior quarter.
- Over five years, EBITDA peaked at $31.7 million in Q4 2025 and troughed at -$22.4 million in Q1 2026.
- A 5-year average of -$6.8 million and a median of -$7.4 million in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2023 and 2025: EBITDA slumped 193.08% in 2023, then jumped 544.16% in 2025.
- A 5-year view of EBITDA shows it stood at -$4.9 million in 2022, then retreated by 20.22% to -$5.9 million in 2023, then slipped by 21.87% to -$7.1 million in 2024, then jumped by 544.16% to $31.7 million in 2025, then slumped by 170.71% to -$22.4 million in 2026.
- Business Quant data shows FBRX's EBITDA at -$22.4 million in Q1 2026, $31.7 million in Q4 2025, and -$17.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - | -22.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.44 Mn |
| Dec 31, 2025 | 31.74 Mn |
| Sep 30, 2025 | -17.69 Mn |
| Jun 30, 2025 | -11.25 Mn |
| Mar 31, 2025 | -15.67 Mn |
| Dec 31, 2024 | -7.15 Mn |
| Sep 30, 2024 | -8.38 Mn |
| Jun 30, 2024 | -12.52 Mn |
| Mar 31, 2024 | -7.43 Mn |
| Dec 31, 2023 | -5.86 Mn |
| Sep 30, 2023 | -9.96 Mn |
| Jun 30, 2023 | -8.90 Mn |
| Mar 31, 2023 | -6.75 Mn |
| Dec 31, 2022 | -4.88 Mn |
| Sep 30, 2022 | -3.40 Mn |
| Jun 30, 2022 | -3.04 Mn |
| Mar 31, 2022 | -2.51 Mn |
| Dec 31, 2021 | -3.30 Mn |
| Sep 30, 2021 | -7.70 Mn |
| Jun 30, 2021 | -5.75 Mn |